Literature DB >> 16980990

Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.

M Introna1, M Franceschetti, A Ciocca, G Borleri, E Conti, J Golay, A Rambaldi.   

Abstract

We have used a standardized 21-day expansion protocol to produce cytokine-induced killer (CIK) cells starting from very small amounts of nucleated cells (approximately 15 x 10(6) cells) isolated from cord blood. Mononuclear cells are stimulated with anti CD3 (OKT3) and IFNgamma and then expanded with IL-2. Moreover, we show that washouts of cord blood units bags (at the end of the infusion) may be sufficient to yield almost 500 x 10(6) CIK by the same expansion protocol. CIK cells show strong cytotoxic activity against a variety of tumor target cell lines including B and T lymphomas and myeloid leukemias. More importantly, expanded cord blood-derived CIK cells are cytotoxic against fresh leukemic blasts and express perforin, granzyme and NKG2D molecule at high levels. The same in vitro protocol has already been used to expand CIK cells from peripheral blood of adult donors under GMP conditions and therefore these observations open up the possibility of imagining a future clinical application of leukemia relapse following cord blood transplantation with CIK cells obtained from the same cord blood unit.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980990     DOI: 10.1038/sj.bmt.1705503

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  25 in total

1.  IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.

Authors:  Mike W Helms; Jennifer A Prescher; Yu-An Cao; Steven Schaffert; Christopher H Contag
Journal:  Cancer Immunol Immunother       Date:  2010-06-09       Impact factor: 6.968

2.  Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion.

Authors:  Ana M Frias; Christopher D Porada; Kirsten B Crapnell; Joaquim M S Cabral; Esmail D Zanjani; Graça Almeida-Porada
Journal:  Exp Hematol       Date:  2008-01       Impact factor: 3.084

3.  Expansion of human hematopoietic stem cells for transplantation: trends and perspectives.

Authors:  Hera Andrade-Zaldívar; Leticia Santos; Antonio De León Rodríguez
Journal:  Cytotechnology       Date:  2008-03-29       Impact factor: 2.058

4.  Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.

Authors:  Ginna G Laport; Kevin Sheehan; Jeanette Baker; Randall Armstrong; Ruby M Wong; Robert Lowsky; Laura J Johnston; Judith A Shizuru; David Miklos; Sally Arai; Jonathan E Benjamin; Wen-Kai Weng; Robert S Negrin
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-25       Impact factor: 5.742

5.  Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.

Authors:  Virna Marin; Irene Pizzitola; Valentina Agostoni; Greta Maria Paola Giordano Attianese; Helene Finney; Alastair Lawson; Martin Pule; Raphael Rousseau; Andrea Biondi; Ettore Biagi
Journal:  Haematologica       Date:  2010-08-16       Impact factor: 9.941

6.  A comparison between cytokine- and bead-stimulated polyclonal T cells: the superiority of each and their possible complementary role.

Authors:  Weng-Chee Chan; Yeh-Ching Linn
Journal:  Cytotechnology       Date:  2014-12-07       Impact factor: 2.058

Review 7.  Cytokine-induced NK-like T cells: from bench to bedside.

Authors:  Yeh Ching Linn; Kam M Hui
Journal:  J Biomed Biotechnol       Date:  2010-03-30

Review 8.  Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors.

Authors:  Maël Heiblig; Mohamed Elhamri; Mauricette Michallet; Xavier Thomas
Journal:  World J Stem Cells       Date:  2015-08-26       Impact factor: 5.326

Review 9.  Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.

Authors:  A Rambaldi; E Biagi; C Bonini; A Biondi; M Introna
Journal:  Leukemia       Date:  2014-06-12       Impact factor: 11.528

10.  Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.

Authors:  Chiara F Magnani; Giuseppe Gaipa; Federico Lussana; Daniela Belotti; Giuseppe Gritti; Sara Napolitano; Giada Matera; Benedetta Cabiati; Chiara Buracchi; Gianmaria Borleri; Grazia Fazio; Silvia Zaninelli; Sarah Tettamanti; Stefania Cesana; Valentina Colombo; Michele Quaroni; Giovanni Cazzaniga; Attilio Rovelli; Ettore Biagi; Stefania Galimberti; Andrea Calabria; Fabrizio Benedicenti; Eugenio Montini; Silvia Ferrari; Martino Introna; Adriana Balduzzi; Maria Grazia Valsecchi; Giuseppe Dastoli; Alessandro Rambaldi; Andrea Biondi
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.